Shots: The acquisition is focus on development of vaccines for adenovirus types 4 and 7, and expanding the company’s vaccine product portfolio Emergent to pay an upfront ~$270M in cash to get hold of PaxVax’s two marketed vaccines- Vivotif and Vaxchora and pipeline products Vivotif (Typhoid Vaccine Live Oral Ty21a), and Vaxchora (Cholera Vaccine, Live, […]Read More
